Stavanger Univ. Hosp.-Rogaland Hosp.
- Address
- Gerd Ragna Block Thorsens gt 8, 4011 Stavanger, Norway
Stavanger University Hospital - Rogaland Hospital
Stavanger University Hospital - Rogaland Hospital is a prominent clinical research institution actively engaged in advanced hematologic malignancy research. The center specializes in evaluating novel therapeutic approaches for blood cancers, with particular emphasis on acute leukemia and related myeloid disorders.
- Phase III clinical trials in acute myeloid leukemia (AML)
- Combination therapy protocols with targeted agents like venetoclax
- Treatment strategies for myelodysplastic syndromes with excess blasts
The hospital contributes to international research efforts investigating event-free survival outcomes in patients with newly diagnosed AML. Their research portfolio includes randomized, placebo-controlled studies examining the integration of targeted therapies with traditional induction and consolidation chemotherapy regimens, aiming to improve remission rates and long-term survival for patients with aggressive hematologic malignancies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Odense University Hospital1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 112 other sites in Norway
Therapeutic Area Benchmark — Norway
Select a therapeutic area to compare against other sites in Norway.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Norway
Market Share
Country: Norway
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Stavanger Univ. Hosp.-Rogaland Hosp.
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Tenofovir Alafenamide as an Adjunct to Anti-CD20 Therapy in Reducing Neuronal Damage in Multiple Sclerosis: A Phase 2b Randomized Controlled Trial | Oslo University Hospital HF | Phase II | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 1 | Unknown | 2022-09-13 | 2022-09-13 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.